Exodus Point Capital Management, LP Iveric Bio, Inc. Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$18.67 - $24.56 $1.17 Million - $1.54 Million	62,666 New	62,666 $1.53 Million
Q3 2022 Nov 10, 2022	BUY	$9.4 - $18.59 $69,334 - $137,119	7,376 Added 6.1%	128,324 $2.3 Million
Q2 2022 Aug 19, 2022	SELL	$9.12 - $18.9 $4,514 - $9,355	-495 Reduced 0.41%	120,948 $1.16 Million
Q1 2022 May 13, 2022	BUY	$12.15 - $16.83 $1.48 Million - $2.04 Million	121,443 New	121,443 $2.04 Million
Q3 2021 Nov 15, 2021	SELL	$7.07 - $17.5 $86,437 - $213,955	-12,226 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$5.69 - $7.17 $69,565 - $87,660	12,226 New	12,226 $77,000
Q1 2021 May 17, 2021	SELL	$5.08 - $6.89 $332,094 - $450,419	-65,373 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$5.65 - $7.66 $369,357 - $500,757	65,373 New	65,373 $452,000
Q2 2020 Aug 14, 2020	SELL	$3.06 - $6.6 $318,579 - $687,132	-104,111 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.83 - $8.44 $181,224 - $540,472	64,037 Added 159.8%	104,111 $358,000
Q4 2019 Feb 14, 2020	BUY	$0.93 - $8.58 $37,268 - $343,834	40,074 New	40,074 $344,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.